Archive for the ‘Research and development’ Category
Emergent BioSolutions to Acquire Trubion Pharmaceuticals
Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income
ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]
August 19, 2010
Tags: Biosolutions, Board of Directors, Common stock, Emergent BioSolutions, Seattle, Stock, Systemic Lupus Erythematosus, Trubion Pharmaceuticals Posted in: Africa, Anthrax vaccines, Biosolutions, Emergent BioSolutions, Health Care, Management, Research and development, Share, Trubion Pharmaceuticals, fuad el-hibri 
No Comments
Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland
ROCKVILLE, MD, May 13, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland’s (TCM) Annual Tech Awards. This award acknowledges the company that best exemplifies the spirit of Maryland’s biotechnology community as well as its presence and leadership within the [...]
May 18, 2010
Tags: Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, Research and development, Tech Council of Maryland Posted in: CEO, Department of Health and Human Services, Emergent BioSolutions, Research and development, Tech Council of Maryland, fuad el-hibri No Comments